A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6 VALENT OspA-BASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS ≥5 YEARS OF AGE
Latest Information Update: 28 Mar 2024
At a glance
- Drugs VLA 15 (Primary)
- Indications Lyme disease
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms VALOR
- Sponsors Pfizer; Valneva
- 21 Mar 2024 Planned number of patients changed from 18000 to 8318.
- 21 Mar 2024 Planned End Date changed from 22 Dec 2025 to 26 Dec 2025.
- 21 Mar 2024 Planned primary completion date changed from 22 Dec 2025 to 26 Dec 2025.